Company Overview and News

0
NZ dollar extends decline as greenback

14h nzherald.co.nz
The New Zealand dollar fell in Asia after upbeat comments overnight from Federal Reserve chair Jerome Powell reinforced the view US rates will keep rising while domestic rates stay at a record low.
WBC WBC WEBNF WBK

10
Wall Street gains on Powell comments, rosy earnings expectations

21h malaymail
NEW YORK, July 18 — Wall Street pushed higher yesterday as investors looked to Federal Reserve Chairman Jerome Powell’s optimistic view of the US economy and as solid earnings supported expectations of a strong second-quarter reporting season.
FB GS.PRB GS.PRA NFLX GS GLSSP JBK WBC GSC GS.PRICL TFG WEBNF WBK GSJ GS.PRJ GS.PRI NDAQ WBC GS.PRD GS.PRC TRI GJS GS.PRN UNH GS.PRK

10
Wall Street gains on Powell comments, rosy earnings expectations

23h channelnewsasia
NEW YORK: Wall Street pushed higher on Tuesday (Jul 17) as investors looked to Federal Reserve Chairman Jerome Powell's optimistic view of the US economy and as solid earnings supported expectations of a strong second-quarter reporting season.
FB GS.PRB GS.PRA NFLX GS GLSSP JBK WBC GSC GS.PRICL TFG WEBNF WBK GSJ GS.PRJ GS.PRI NDAQ WBC GS.PRD GS.PRC TRI GJS GS.PRN UNH GS.PRK

10
Wall St. gains on Powell comments, rosy earnings expectations

2018-07-17 channelnewsasia
U.S. stock index futures fell on Tuesday as Netflix's weak subscriber numbers weighed on high-flying technology stocks and health insurer UnitedHealth Group's results failed to impress investors.
FB GS.PRB GS.PRA NFLX GS GLSSP JBK WBC GSC GS.PRICL TFG WEBNF WBK GSJ GS.PRJ GS.PRI NDAQ WBC GS.PRD GS.PRC TRI GJS GS.PRN UNH GS.PRK

0
NZ dollar heading for 0.4% weekly decline against the greenback

2018-07-13 nzherald.co.nz
The New Zealand dollar is heading for a 0.4 per cent weekly decline having lurched more than 1 US cent during the week in response to the US announcement that it plans to impose tariffs on a further US$200 billion ($295.4b) of Chinese imports.
WBC WBC WEBNF WBK

0
NZ shares rise as Infratil and Z gain

2018-07-13 nzherald.co.nz
New Zealand shares gained in light trading, led higher by Infratil and Z Energy, while Tourism Holdings and Fisher & Paykel Healthcare Corp fell.
ZNZ WBC SKC THL WBC ZNRGF WEBNF WBK ZEL

0
NZ shares drop as A2 weakens on trading update

2018-07-12 nzherald.co.nz
New Zealand shares fell, led lower by A2 Milk Co and Sky Network Television, while Kathmandu Holdings hit a four-and-a-half year high.
KTHDY WBC AIR WEBNF WBK ANZFY AIZ KMD SKT SYKWF WBC ANZLY SKKTY ANZFF KMD

0
Dollar falls as US-China trade tensions dominate

2018-07-12 nzherald.co.nz
The New Zealand dollar fell amid expectations China will retaliate for the latest tariffs the US has announced on Chinese imports, which has weighed on prices of commodities and commodity-linked currencies.
WBC WBC WEBNF WBK

0
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

0
NZ shares mixed in light trading, Sky TV and Stride rise while A2, Westpac drop

2018-07-04 nzherald.co.nz
New Zealand shares were mixed in light trading, with Sky Network Television and Stride Property leading gains while A2 Milk Co and Westpac Banking Corp fell.
AIA WBC WEBNF WBK ACKDF AUKNY SKT SYKWF AIA WBC VTHPF SKKTY GTK SML

0
Dollar shrugs off weak dairy prices to rise against greenback

2018-07-04 nzherald.co.nz
The New Zealand dollar shrugged off a weak dairy auction and pushed higher against the greenback as investors pared back slightly on their expectations that the kiwi might continue to fall.
WBC WBC WEBNF WBK

0
Macquarie to scrap commissions on sales of own wealth products

2018-07-03 theage.com.au
Macquarie Group's wealth management advisers will stop taking commissions for selling the company's products, a practice widely expected to be outlawed following the banking royal commission.
MQBKY WBC WBC WEBNF MCQEF WBK MQG

0
Macquarie to scrap commissions on sales of own wealth products

2018-07-03 smh.com.au
Macquarie Group's wealth management advisers will stop taking commissions for selling the company's products, a practice widely expected to be outlawed following the banking royal commission.
MQBKY WBC WBC WEBNF MCQEF WBK MQG

14
5 Bank Stocks That Pay Big Dividends to Shareholders | InvestorPlace

2018-06-29 investorplace
The banking sector — and bank stocks — saw an intriguing reversal in the 21st century.
HCS.PRB WBC NYCB.PRA NYCB.PRU WEBNF WBK HCS HSB 0005 WBC HSEA NYCB HSEB HSBC.PRA HSBC ORIT BLX HBCYF

26
NZ shares taper off in strong June quarter

2018-06-29 nzherald.co.nz
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to NZX:WBC / Westpac Banking Corporation on message board site Silicon Investor.

East-West Bankcorp (EWBC) WBCG, formerly SHAL
Web Capital Group (WBCG), mini-CMGI CWBC Community West Bancshares